Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chung, Hye J. | - |
dc.contributor.author | Lee, Myung G. | - |
dc.date.accessioned | 2024-01-21T02:30:28Z | - |
dc.date.available | 2024-01-21T02:30:28Z | - |
dc.date.created | 2021-08-31 | - |
dc.date.issued | 2006-10 | - |
dc.identifier.issn | 0142-2782 | - |
dc.identifier.uri | https://pubs.kist.re.kr/handle/201004/135095 | - |
dc.description.abstract | Pharmacokinetic parameters of ipriflavone were compared after intravenous (20 mg/kg) and oral (200 mg/kg) administration in control rats and in rats with acute renal failure induced by uranyl nitrate (U-ARF rats). It was expected that the time-averaged nonrenal clearance (Cl-nr) of ipriflavone in U-ARF rats could be significantly slower than in the control rats, since it was reported that ipriflavone was metabolized via the hepatic microsomal cytochrome P450 (CYP) 1A1/2 and 2C11 and the expression and mRNA level of CYP1A2 were not changed, but those of CYP2C11 were decreased in U-ARF rats compared with control rats. Unexpectedly, after intravenous administration in U-ARF rats, the Cl-nr, of ipriflavone was significantly faster than in the controls (40.8 compared with 29.0ml/min/kg). This may be due to an increase in the glucuronide conjugate formation of ipriflavone metabolites in U-ARF rats. After oral administration of ipriflavone in U-ARF rats, the AUC(0-24h) was significantly smaller (194 compared with 295 mu g min/ml) than in the controls. Copyright (c) 2006 John Wiley & Sons, Ltd. | - |
dc.language | English | - |
dc.publisher | JOHN WILEY & SONS LTD | - |
dc.subject | POSTMENOPAUSAL OSTEOPOROSIS | - |
dc.subject | CYP2E1 INDUCTION | - |
dc.subject | DOSAGE REGIMENS | - |
dc.subject | PLASMA | - |
dc.subject | BONE | - |
dc.subject | METABOLITES | - |
dc.subject | LIVER | - |
dc.title | Pharmacokinetic changes of ipriflavone in rats with acute renal failure induced by uranyl nitrate | - |
dc.type | Article | - |
dc.identifier.doi | 10.1002/bdd.515 | - |
dc.description.journalClass | 1 | - |
dc.identifier.bibliographicCitation | BIOPHARMACEUTICS & DRUG DISPOSITION, v.27, no.7, pp.345 - 351 | - |
dc.citation.title | BIOPHARMACEUTICS & DRUG DISPOSITION | - |
dc.citation.volume | 27 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 345 | - |
dc.citation.endPage | 351 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.identifier.wosid | 000241997900005 | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | POSTMENOPAUSAL OSTEOPOROSIS | - |
dc.subject.keywordPlus | CYP2E1 INDUCTION | - |
dc.subject.keywordPlus | DOSAGE REGIMENS | - |
dc.subject.keywordPlus | PLASMA | - |
dc.subject.keywordPlus | BONE | - |
dc.subject.keywordPlus | METABOLITES | - |
dc.subject.keywordPlus | LIVER | - |
dc.subject.keywordAuthor | ipriflavone | - |
dc.subject.keywordAuthor | U-ARF | - |
dc.subject.keywordAuthor | pharmacokinetics | - |
dc.subject.keywordAuthor | rats | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.